Cargando…

Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)

BACKGROUND: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiechle, Marion, Engel, Christoph, Berling, Anika, Hebestreit, Katrin, Bischoff, Stephan, Dukatz, Ricarda, Gerber, Wolf-Dieter, Siniatchkin, Michael, Pfeifer, Katharina, Grill, Sabine, Yahiaoui-Doktor, Maryam, Kirsch, Ellen, Niederberger, Uwe, Marter, Nicole, Enders, Ute, Löffler, Markus, Meindl, Alfons, Rhiem, Kerstin, Schmutzler, Rita, Erickson, Nicole, Halle, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165708/
https://www.ncbi.nlm.nih.gov/pubmed/28031860
http://dx.doi.org/10.1186/s40814-016-0114-7
_version_ 1782482877002285056
author Kiechle, Marion
Engel, Christoph
Berling, Anika
Hebestreit, Katrin
Bischoff, Stephan
Dukatz, Ricarda
Gerber, Wolf-Dieter
Siniatchkin, Michael
Pfeifer, Katharina
Grill, Sabine
Yahiaoui-Doktor, Maryam
Kirsch, Ellen
Niederberger, Uwe
Marter, Nicole
Enders, Ute
Löffler, Markus
Meindl, Alfons
Rhiem, Kerstin
Schmutzler, Rita
Erickson, Nicole
Halle, Martin
author_facet Kiechle, Marion
Engel, Christoph
Berling, Anika
Hebestreit, Katrin
Bischoff, Stephan
Dukatz, Ricarda
Gerber, Wolf-Dieter
Siniatchkin, Michael
Pfeifer, Katharina
Grill, Sabine
Yahiaoui-Doktor, Maryam
Kirsch, Ellen
Niederberger, Uwe
Marter, Nicole
Enders, Ute
Löffler, Markus
Meindl, Alfons
Rhiem, Kerstin
Schmutzler, Rita
Erickson, Nicole
Halle, Martin
author_sort Kiechle, Marion
collection PubMed
description BACKGROUND: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factors such as physical activity status, dietary habits, and body weight. The modification of penetrance by changing lifestyle factors has not thus far been investigated in a randomized trial in BRCA mutation carriers. METHODS: Therefore, we intend to enroll 60 BRCA1/2 mutation carriers in a pilot feasibility study (Lifestyle Intervention Study in Women with Hereditary Breast and Ovarian Cancer (LIBRE) pilot). This multi-center, prospective, controlled trial aims to randomize (1:1) participants into a (1) multi-factorial lifestyle intervention group (IG) versus (2) the control group with usual care (CG). The primary endpoint is feasibility and acceptance of a structured interdisciplinary lifestyle intervention program over 12 months (at least 70% of the patients to complete the 1-year intervention). Furthermore, the effects on physical fitness, BMI, quality of life, and stress coping capacity will be investigated. During the first 3 months, women in the IG will receive structured, individualized and mainly supervised endurance training of ≥18 MET*h/week (MET = metabolic equivalent task) and personal nutritional counseling based on the Mediterranean diet. During the subsequent 9 months, the IG will receive monthly group training sessions and regular telephone contacts for motivation, whereas the CG will only receive usual care (one general counseling on healthy nutrition and benefits of regular physical activity on health status). At randomization and subsequent time points (3, 6, 12 months), cardiopulmonary fitness will be assessed by spiroergometry and nutritional and psychological status by validated questionnaires. DISCUSSION: This pilot study will investigate the optimal strategy to improve physical fitness, nutritional habits, and psychological factors in women at high risk for developing breast or ovarian cancer. The results of this pilot feasibility study will be the basis for a larger prospective randomized trial including clinical events (LIBRE). TRIAL REGISTRATION: ClinicalTrials.gov, NCT02087592
format Online
Article
Text
id pubmed-5165708
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51657082016-12-28 Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) Kiechle, Marion Engel, Christoph Berling, Anika Hebestreit, Katrin Bischoff, Stephan Dukatz, Ricarda Gerber, Wolf-Dieter Siniatchkin, Michael Pfeifer, Katharina Grill, Sabine Yahiaoui-Doktor, Maryam Kirsch, Ellen Niederberger, Uwe Marter, Nicole Enders, Ute Löffler, Markus Meindl, Alfons Rhiem, Kerstin Schmutzler, Rita Erickson, Nicole Halle, Martin Pilot Feasibility Stud Study Protocol BACKGROUND: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factors such as physical activity status, dietary habits, and body weight. The modification of penetrance by changing lifestyle factors has not thus far been investigated in a randomized trial in BRCA mutation carriers. METHODS: Therefore, we intend to enroll 60 BRCA1/2 mutation carriers in a pilot feasibility study (Lifestyle Intervention Study in Women with Hereditary Breast and Ovarian Cancer (LIBRE) pilot). This multi-center, prospective, controlled trial aims to randomize (1:1) participants into a (1) multi-factorial lifestyle intervention group (IG) versus (2) the control group with usual care (CG). The primary endpoint is feasibility and acceptance of a structured interdisciplinary lifestyle intervention program over 12 months (at least 70% of the patients to complete the 1-year intervention). Furthermore, the effects on physical fitness, BMI, quality of life, and stress coping capacity will be investigated. During the first 3 months, women in the IG will receive structured, individualized and mainly supervised endurance training of ≥18 MET*h/week (MET = metabolic equivalent task) and personal nutritional counseling based on the Mediterranean diet. During the subsequent 9 months, the IG will receive monthly group training sessions and regular telephone contacts for motivation, whereas the CG will only receive usual care (one general counseling on healthy nutrition and benefits of regular physical activity on health status). At randomization and subsequent time points (3, 6, 12 months), cardiopulmonary fitness will be assessed by spiroergometry and nutritional and psychological status by validated questionnaires. DISCUSSION: This pilot study will investigate the optimal strategy to improve physical fitness, nutritional habits, and psychological factors in women at high risk for developing breast or ovarian cancer. The results of this pilot feasibility study will be the basis for a larger prospective randomized trial including clinical events (LIBRE). TRIAL REGISTRATION: ClinicalTrials.gov, NCT02087592 BioMed Central 2016-12-19 /pmc/articles/PMC5165708/ /pubmed/28031860 http://dx.doi.org/10.1186/s40814-016-0114-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Kiechle, Marion
Engel, Christoph
Berling, Anika
Hebestreit, Katrin
Bischoff, Stephan
Dukatz, Ricarda
Gerber, Wolf-Dieter
Siniatchkin, Michael
Pfeifer, Katharina
Grill, Sabine
Yahiaoui-Doktor, Maryam
Kirsch, Ellen
Niederberger, Uwe
Marter, Nicole
Enders, Ute
Löffler, Markus
Meindl, Alfons
Rhiem, Kerstin
Schmutzler, Rita
Erickson, Nicole
Halle, Martin
Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
title Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
title_full Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
title_fullStr Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
title_full_unstemmed Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
title_short Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
title_sort lifestyle intervention in brca1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (libre-1 study)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165708/
https://www.ncbi.nlm.nih.gov/pubmed/28031860
http://dx.doi.org/10.1186/s40814-016-0114-7
work_keys_str_mv AT kiechlemarion lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT engelchristoph lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT berlinganika lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT hebestreitkatrin lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT bischoffstephan lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT dukatzricarda lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT gerberwolfdieter lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT siniatchkinmichael lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT pfeiferkatharina lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT grillsabine lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT yahiaouidoktormaryam lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT kirschellen lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT niederbergeruwe lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT marternicole lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT endersute lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT lofflermarkus lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT meindlalfons lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT rhiemkerstin lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT schmutzlerrita lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT ericksonnicole lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study
AT hallemartin lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study